Menopausal hormone therapy and breast cancer mortality: clinical implications

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Therapeutic Advances in Drug Safety

• Publication date

  2015-01-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2042098614568300PMID 25922653PMCID PMC4406918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interactions of Hormone Replacement Therapy, Body Weight, and Bilateral Oophorectomy in Breast Cancer Risk

  2014cited by this paper
• Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy

  2014cited by this paper
• Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort

  2014cited by this paper
• Systematic review about breast cancer incidence in relation to hormone replacement therapy use

  2014cited by this paper
• Women's Health Initiative

  2014cited by this paper
• Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate

  2014cited by this paper
• Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.

  2014cited by this paper
• Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

  2013cited by this paper
• Pre-diagnosis oophorectomy, estrogen therapy and mortality in a cohort of women diagnosed with breast cancer

  2013cited by this paper
• Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.

  2013cited by this paper
• Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

  2013cited by this paper
• Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.

  2012influential reference
• Changing concepts: Menopausal hormone therapy and breast cancer.

  2012cited by this paper
• A Sustained Decline in Postmenopausal Hormone Use: Results From the National Health and Nutrition Examination Survey, 1999–2010

  2012cited by this paper
• Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer

  2012cited by this paper
• Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study

  2012cited by this paper
• Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy

  2011cited by this paper
• Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced Apoptosis

  2011cited by this paper
• Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009

  2011cited by this paper
• Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries

  2011cited by this paper
• Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer

  2011cited by this paper
• An epidemiological overview of the relationship between hormone replacement therapy and breast cancer

  2011cited by this paper
• The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment.

  2011cited by this paper
• Significant fall in hormone replacement therapy prescription in general practice.

  2010cited by this paper
• Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy.

  2010cited by this paper
• Hormone therapy and fatal breast cancer

  2010cited by this paper
• Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

  2010cited by this paper
• Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

  2010cited by this paper
• Factors Associated With Undergoing Bilateral Salpingo-oophorectomy at the Time of Hysterectomy for Benign Conditions

  2009cited by this paper
• Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?

  2009cited by this paper
• Breast cancer after use of estrogen plus progestin in postmenopausal women.

  2009cited by this paper
• Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

  2009cited by this paper
• Mammographic screening and risk factors for breast cancer.

  2009cited by this paper
• Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.

  2008cited by this paper
• Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.

  2008cited by this paper
• Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer

  2008cited by this paper
• Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers

  2008cited by this paper
• Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study

  2008cited by this paper
• Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.

  2007cited by this paper
• The decrease in breast-cancer incidence in 2003 in the United States.

  2007cited by this paper
• Fibroids (uterine myomatosis, leiomyomas).

  2007cited by this paper
• Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

  2006cited by this paper
• Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence.

  2006cited by this paper
• [Incidence of breast cancer before and after implementation of mammography screening].

  2006cited by this paper
• Brystkreftforekomst før og etter innføring av mammografiscreening

  2006cited by this paper
• Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study

  2005cited by this paper
• Comparative analysis of breast cancer risk factors among African-American women and White women.

  2005cited by this paper
• Fibroids (uterine myomatosis, leiomyomas).

  2005cited by this paper
• Symptom Experience After Discontinuing Use of Estrogen Plus Progestin

  2005cited by this paper
• Symptom experience after discontinuing use of estrogen plus progestin.

  2005cited by this paper
• Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial.

  2004cited by this paper
• National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

  2004cited by this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cited by this paper
• Fibroids (uterine myomatosis, leiomyomas).

  2004cited by this paper
• Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.

  2003cited by this paper
• Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial

  2003cited by this paper
• Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

  2003cited by this paper
• Breast cancer and hormone-replacement therapy in the Million Women Study.

  2003cited by this paper
• Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it.

  2003cited by this paper
• Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.

  2003influential reference
• Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

  2003cited by this paper
• Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Postmenopausal hormone replacement therapy: scientific review.

  2002cited by this paper
• Postmenopausal Hormone Use, Screening, and Breast Cancer: Characterization and Control of a Bias

  2001cited by this paper
• Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

  2000cited by this paper
• Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

  1997cited by this paper
• Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.

  1996cited by this paper
• The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

  1995cited by this paper
• Concordance of self-reported data and medical record audit for six cancer screening procedures.

  1993cited by this paper
• A case-control study of menopausal estrogen therapy and breast cancer.

  1980cited by this paper
• MENOPAUSAL ESTROGENS AND BREAST CANCER

  1977cited by this paper
• Menopausal estrogens and breast cancer.

  1976cited by this paper

• Cost-Utility Analysis of Traditional Korean Medicine without Acupuncture Claims versus Integrative Care for Menopausal Disorders: A Nationwide Retrospective Cohort Study

  2026cites this paper
• Genetic Insights into Breast Cancer in Northeastern Mexico: Unveiling Gene–Environment Interactions and Their Links to Obesity and Metabolic Diseases

  2025cites this paper
• Long-term hormone therapy for perimenopausal and postmenopausal women.

  2025cites this paper
• Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis

  2024cites this paper
• Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk

  2022cites this paper
• Modulation of inflammatory markers by petroleum ether fraction of Trigonella foenum-graecum L. seed extract in ovariectomized rats.

  2021cites this paper
• Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.

  2020cites this paper
• Herbal Medicines (Danggui Liuhuang Decoctions) for Management of Menopausal Symptoms: A Systematic Review of Randomized Controlled Trials

  2020cites this paper
• Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer

  2019cites this paper
• Interface Between Oral and Systemic Disease

  2019cites this paper
• A Comparison of Mammography and Ultrasonography in the Evaluation of Breast Masses in Early Stage

  2018cites this paper
• Analyzing factors associated with decisional stage of adopting breast cancer screening among Korean American women using precaution adoption process model

  2018cites this paper
• Pattern of mortality after menopausal hormone therapy: long‐term follow up in a population‐based cohort

  2018cites this paper
• Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence

  2018cites this paper
• Progesterone, progestins and the breast in menopause treatment

  2018cites this paper
• A role for G-protein coupled estrogen receptor (GPER) in estrogen-induced carcinogenesis: Dysregulated glandular homeostasis, survival and metastasis.

  2018cites this paper
• The Relation of Obesity-Related Hormonal and Cytokine Levels With Multiple Myeloma and Non-Hodgkin Lymphoma

  2018cites this paper
• Impact of microbiota on the use and effects of isoflavones in the relief of climacteric symptoms in menopausal women – A review

  2018cites this paper
• Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women’s Health Initiative

  2017cites this paper
• A Comparative Study on the WCRF International/University of Bristol Methodology for Systematic Reviews of Mechanisms Underpinning Exposure–Cancer Associations

  2017cites this paper
• Perinatal Exposure to Bisphenol A or Diethylstilbestrol Increases the Susceptibility to Develop Mammary Gland Lesions After Estrogen Replacement Therapy in Middle-Aged Rats

  2017cites this paper
• Survey of Breast Cancer Incidence in the Middle East and the United States

  2017cites this paper
• Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies

  2017cites this paper
• Long-term hormone therapy for perimenopausal and postmenopausal women.

  2017cites this paper
• Hormone Replacement Therapy ( including Benefits and Risks )

  2016cites this paper
• Design, synthesis, and anti-breast cancer evaluation of new triarylethylene analogs bearing short alkyl- and polar amino-/amido-ethyl chains.

  2016cites this paper
• Pause menopause with Rhodiola rosea, a natural selective estrogen receptor modulator.

  2016cites this paper
• The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections

  2016cites this paper
• Lack of Evidence for a Relationship between High Risk Human Papillomaviruses and Breast Cancer in Iranian Patients.

  2016cites this paper
• Update on menopausal hormone therapy

  2015cites this paper
• NON-PHENOLIC GESTODENE METABOLITES ENZYMATICALLY FORMED IN MCF-7 BREAST CANCER CELLS EFFICIENTLY INDUCE THE CELL PROLIFERATION

  2015cites this paper
• Is hormone therapy during climacteric for all?

  2015cites this paper
• European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer.

  2015cites this paper
• Systematic review about breast cancer incidence in relation to hormone replacement therapy use

  2014cites this paper